Weight-loss drugs to get surprising endorsement from global health giant
The organization plans to back GLP-1s like Wegovy and Zepbound to treat obesity in adults as part of a shift in addressing the global obesity epidemic, as reported by Reuters.
In a memo, the agency called for strategies to improve access to the medications in countries that are low- and middle-income, Reuters summarized.
'Oatzempic' Diet Drink For Weight Loss: Does It Work And Is It Safe?
More than one billion people have obesity across the globe, according to WHO's data, and around 70% of these individuals live in low- and middle-income countries.
The proven effectiveness of weight-loss drugs has led individuals, especially in the U.S. and other high-income countries like Britain and Germany, to seek out GLP-1 solutions.
Read On The Fox News App
For more Lifestyle articles, visit foxnews.com/lifestyle
Cost can be a factor, however, as the medications can be priced at more than $1,000 per month, Reuters noted.
In a statement, a WHO spokesperson wrote that the agency has been working on a "set of new recommendations for obesity prevention, care and treatment" among different age groups, including children, adolescents and adults.
Click Here To Sign Up For Our Lifestyle Newsletter
The agency said it expects the drug recommendations to be finalized by August or September 2025.
The guidance will also include "how and when this class of medications may be integrated as one component of a chronic care model that includes both clinical and lifestyle interventions," the WHO stated.
WHO experts also plan to meet next week to decide whether GLP-1 drugs should be included on the agency's list of essential medications to treat both obesity and type 2 diabetes.
The agency is also reportedly calling for longer-term studies on the cost-effectiveness of these drugs "across all settings" and income statuses.Original article source: Weight-loss drugs to get surprising endorsement from global health giant
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
40 minutes ago
- Business Wire
WHO and UNICEF to Launch Polio Vaccination Campaign
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign sponsored by the National Emergency Operation Center (NEOC) Afghanistan, UNICEF, WHO, and other GPEI partners starting in August 2025. Focused on the Eastern region of Afghanistan, the campaign will deploy Tropis ID to administer 1.3 million fractional doses of inactivated polio vaccine (fIPV) to children ages 5 and under in parallel to oral polio vaccine (OPV) administration as part of a WHO-recommended strategy to boost humoral and mucosal immunity. Poliovirus has been eliminated in most parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site immunization, a strategy where vaccination services are offered at multiple, convenient locations. This approach is expected to help increase immunization coverage, particularly in high-risk areas. The Technical Advisory Group (TAG) on polio eradication endorsed the Afghanistan program's 'Strategic Reset' to optimize site-to-site vaccination, while stressing the need for stronger leadership, community acceptance, and broad government engagement. Including Tropis ID fIPV in this immunization program supports Afghanistan's polio eradication goals to eliminate persistent virus lineages in the East, prevent new WPV1 cases in the East and South Regions, and prevent local transmission in other parts of the country. 1 'We are pleased to be partnering with UNICEF, WHO, and NEOC Afghanistan in their continued efforts to eradicate polio,' said Paul LaBarre, Senior Vice President Global Business Development, PharmaJet. 'We aim to achieve high impact in the fight against poliovirus, including increased coverage, decreased costs, and high acceptability 2 previously seen with Tropis ID delivered fIPV in Pakistan, 2 Somalia, 3 and Nigeria 4.' Refer to Instructions for Use to ensure safe injections and to review risks. About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About the NEOC Afghanistan NEOC Afghanistan is led by the Ministry of Public Health and the core members are WHO, UNICEF, BMGF, CDC, Rotary International, Core Group of Polio Project (CGPP), EPI manager and the National Polio Focal Point. About the Global Polio Eradication Initiative (GPEI) 5 The Global Polio Eradication Initiative is a public-private partnership led by national governments with six partners – the World Health Organization (WHO), Rotary International, the US Centers for Disease Control and Prevention (CDC), the United Nations Children's Fund (UNICEF), Gates Foundation and Gavi, the vaccine alliance. Its goal is to eradicate polio worldwide. Launched in 1988 after the World Health Assembly passed a resolution to eradicate polio, the Global Polio Eradication Initiative, along with its partners, has helped countries to make huge progress in protecting the global population from this debilitating disease. As a result, the global incidence of polio has decreased by 99.9% since GPEI's foundation. An estimated 20 million people today are walking who would otherwise have been paralyzed by the disease, and more than 1.5 million people are alive, whose lives would otherwise have been lost. Now the task remains to tackle polio in its last few strongholds and get rid of the final 0.1% of polio cases including the two remaining endemic countries: Pakistan and Afghanistan. 1 World Health Organization, Global Polio Eradication Initiative, Technical Advisory Group urges strong action to eradicate polio in Afghanistan, February 26, 2025 2 Daly, C et al, Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, Vaccine, Volume 38 Issue 8, 18 February, 2020, Pages 1893-1898 3 Nouh, K et al, Use of a fractional dose of inactivated polio vaccine (fIPV) to increase IPV coverage among children under 5 years of age in Somalia, Springer Nature Volume 2 article number 16 (2024) 4 Biya, O et al, Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine — Sokoto State, Nigeria, November 2022, CDC Morbidity and Mortality Weekly report, November 24, 2023 / 72(47);1290–1291 5 Global Polio Eradication Initiative, who we are:
Business Insider
an hour ago
- Business Insider
Little Mix's Jade Thirlwall says she faces a 'daily battle' not to go on Ozempic
Little Mix 's Jade Thirlwall says she is resisting Ozempic despite the public scrutiny around her body. In an interview with The Guardian published Saturday, the singer said that many of the negative comments she receives are about weight gain. "I have a daily battle with myself not to go on Ozempic," Thirlwall told The Guardian. "I don't judge people that do, but because I have a history of eating disorders, I don't know where taking something like that would end for me." Thirlwall said she had only been out of the hospital for a few months after treatment for anorexia when she auditioned for " The X Factor" in 2011 at 18. "Historically, if I've ever felt that something is out of my control, then restricting food has been a means of controlling my life in a very toxic way," she said. Little Mix was formed on "The X Factor" in 2011, comprising Thirlwall, Leigh-Anne Pinnock, Perrie Edwards, and Jesy Nelson. Nelson left the group in 2020 amid backlash over Blackfishing, and in 2022, the band went on hiatus to focus on their solo careers. Thirlwall said that much of the scrutiny around her body comes from people comparing her to her younger self. "Now I'm in my 30s and the healthiest I've ever been, but every time I post a picture, there are comments saying, 'She must be pregnant.' The sad thing is that it's usually women," Thirlwall said. "But people are used to seeing me in a group environment five or 10 years ago when I was stick-thin because I was in my early 20s with an eating disorder," she said. A representative for Thirlwall did not immediately respond to a request for comment sent by Business Insider outside regular hours. Ozempic and Wegovy are brand names for semaglutide, an injectable drug originally developed for diabetes. In 2021, the FDA approved semaglutide for use in weight management. The drug works by regulating hunger signals, allowing people to feel full while eating less. However, it has side effects such as nausea, diarrhea, and constipation. Some patients also reported feeling disgusted by the foods they used to enjoy. Dr. Francesco Rubino, the chair of metabolic and bariatric surgery at King's College London, told Business Insider in 2022 that it was common for people to regain the weight after stopping treatment. Several doctors also told Business Insider in July that they've seen a sharp increase in patients on GLP-1 medications when they enter treatment for eating disorders. In recent years, many Hollywood celebrities have addressed speculation about whether they've used weight-loss drugs. In May 2023, NBA star Charles Barkley said he lost over 60 pounds in six months after taking Mounjaro while eating healthily and exercising. Later that year, in December 2023, Oprah Winfrey said she uses weight-loss medication to help manage her weight. Meanwhile, stars such as Lizzo, Kelly Clarkson, and Jesse Plemons, have denied using such medications, attributing their weight loss instead to lifestyle changes.
New York Times
2 hours ago
- New York Times
A Debilitating Virus Surges Globally as Mosquitoes Move With Warming Climate
A mosquito-borne virus that can leave infected people debilitated for years is spreading to more regions of the world, as climate change creates new habitats for the insects that carry it. More than 240,000 cases of the virus, chikungunya, have been reported around the world so far this year, including 200,000 cases in Latin America and 8,000 in China, the first cases ever reported there. Chinese authorities have launched an urgent effort to try to stifle the virus with public health measures that evoke the response to Covid-19. Chikungunya is not circulating in the United States or Canada, but cases have been reported in France and Italy. The disease is endemic in Mexico. The World Health Organization is warning that current transmission patterns resemble a global outbreak that infected 500,000 people 20 years ago, contributing to a surge of new disabilities. Although it is rarely fatal, chikungunya causes excruciating and prolonged joint pain and weakness. 'You have people who were working, with no disabilities, and from one day to the next, they cannot even type on a phone, they can't hold a pen, a woman cannot even hold a knife to be able to cook for her family,' said Dr. Diana Rojas Alvarez, who leads chikungunya work at the W.H.O. 'It really impacts quality of life and also the economy of the country.' What is chikungunya, and how dangerous is it? Chikungunya is a virus from the same family as Zika and dengue fever. Two different species of mosquitoes, Aedes aegypti and Aedes albopictus, transmit chikungunya. Between four and eight days after a bite, a person can develop symptoms including fever, joint pain and a rash. Want all of The Times? Subscribe.
